Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Noxopharm Ltd. ( (AU:NOX) ) is now available.
Noxopharm Limited has significantly reduced its holding in Nyrada Inc., decreasing its voting power from 18.60% to 5.13%. This change in substantial holding may impact Nyrada’s shareholder dynamics and influence within the company, potentially affecting its strategic decisions and market perception.
More about Noxopharm Ltd.
Nyrada Inc. is a biotechnology company specializing in the discovery and development of innovative small-molecule therapies. The company focuses on targeting Transient Receptor Potential Canonical (TRPC) ion channels, with its lead candidate, NYR-BI03, currently undergoing a Phase I clinical trial for neuroprotection and cardioprotection. Nyrada is incorporated in Delaware, USA.
Average Trading Volume: 93,059
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$20.46M
For a thorough assessment of NOX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money